Phase II study of spirogermanium in the treatment of metastatic breast cancer.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D005857:Germanium / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009942:Organometallic Compounds; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium